TherapeutAix adds Immunoconsulting to global R&D Network
We are pleased to announce that we have grown our global R&D Network with the addition of ImmunoConsulting Ltd. ImmunoConsulting,…
Recent study highlights the challenges in developing treatments for NASH
We previously commented on the failure of the ASK-1 inhibitor, selonsertib, in the STELLAR-4 phase III study in patients with compensated…
TherapeutAix/Medicines Discovery Catapult session on drug discovery in fibrotic disease at the BOS Basel event in Switzerland
BOS (Biotech Outsourcing Strategies) Basel 2019 will bring together stakeholders in pharmaceutical R&D outsourcing, who share knowledge, develop skills and…
TherapeutAix are heading to the International Liver Congress at the Annual EASL Meeting
TherapeutAix will be at the EASL conference in Vienna, Austria, from the 10th – 14th April 2019. They will be…
TherapeutAix NASH review article is now available online!
At the end of last year, TherapeutAix published an article titled ‘The future R&D landscape in non-alcoholic steatohepatitis’ in Drug…
